These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12195008)

  • 1. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Olukoga AO
    J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008
    [No Abstract]   [Full Text] [Related]  

  • 2. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Crook MA; Lynas J; Wray R
    J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
    Crook M; Lynas J; Wray R
    J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
    [No Abstract]   [Full Text] [Related]  

  • 5. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
    Oleesky DA; Mir MA
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
    [No Abstract]   [Full Text] [Related]  

  • 6. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 7. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
    Murphy MJ; Duncan A; Vallance BD; Packard CJ; O'Reilly DS
    Postgrad Med J; 1995 Aug; 71(838):498-500. PubMed ID: 7567762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrate monotherapy and profound hypoalphalipoproteinaemia.
    Olukoga AO; Crowley VE; Stewart MF; Weinkove O
    Postgrad Med J; 1996 Mar; 72(845):189. PubMed ID: 8731722
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatinine rise after fibrate therapy in renal graft recipients.
    Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C
    Lancet; 1993 Mar; 341(8848):840. PubMed ID: 8096050
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute rhabdomyolysis after bezafibrate re-exposure.
    Terrovitou CT; Milionis HJ; Elisaf MS
    Nephron; 1998; 78(3):336-7. PubMed ID: 9546698
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fibrate-induced increase in serum creatinine levels: two cases].
    Décaudin B; Beraud G; Lannoy D; Semjen E; Wierre L; Horrent S; Résibois JP; Azar R; Odou P
    Therapie; 2005; 60(6):601-2. PubMed ID: 16555504
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient.
    Panuccio V; Enia G; Parlongo S; Cutrupi S; Zoccali C
    Nephron; 1996; 73(4):736. PubMed ID: 8856294
    [No Abstract]   [Full Text] [Related]  

  • 15. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment.
    Górriz JL; Sancho A; Alcoy E; García-Ramos JL; Pallardó LM
    Nephrol Dial Transplant; 1995 Dec; 10(12):2371-2. PubMed ID: 8808248
    [No Abstract]   [Full Text] [Related]  

  • 16. Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes.
    Lever M; McEntyre CJ; George PM; Slow S; Elmslie JL; Lunt H; Chambers ST; Parry-Strong A; Krebs JD
    Cardiovasc Drugs Ther; 2014 Oct; 28(5):459-68. PubMed ID: 25060556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function changes in diabetic nephropathy induced by bezafibrate.
    Bruce R; Daniels A; Cundy T
    Nephron; 1996; 73(3):490. PubMed ID: 8832617
    [No Abstract]   [Full Text] [Related]  

  • 18. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed bezafibrate-induced angio-oedema in a 68-year-old man.
    Frendo M; Theuma R; Fava S
    Br J Clin Pharmacol; 2007 Oct; 64(4):560-1. PubMed ID: 17610533
    [No Abstract]   [Full Text] [Related]  

  • 20. Warfarin potentiation with bezafibrate.
    Beringer TR
    Postgrad Med J; 1997 Oct; 73(864):657-8. PubMed ID: 9497982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.